Literature DB >> 32699874

Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds.

Göran Schulz1, Catherine Victoria, Andreas Kirschning, Eike Steinmann.   

Abstract

Covering: up to the beginning of 2020Many natural substances have been transformed again and again with regard to their pharmaceutical-medical potential, including new members of a growing class of natural products, the flavaglines. Important representatives are rocaglamide and silvestrol, isolated from the Aglaia species, which are highlighted here. These products started as potential anti-tumor agents five decades ago and have recently proved to be very promising antiviral agents, especially against RNA viruses. Today they are discussed as potential starting compounds for developing drug candidates and therapeutics.

Entities:  

Year:  2020        PMID: 32699874     DOI: 10.1039/d0np00024h

Source DB:  PubMed          Journal:  Nat Prod Rep        ISSN: 0265-0568            Impact factor:   13.423


  9 in total

Review 1.  Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species.

Authors:  Garima Agarwal; Long-Sheng Chang; Djaja Doel Soejarto; A Douglas Kinghorn
Journal:  Planta Med       Date:  2021-03-30       Impact factor: 3.007

2.  The eIF4A Inhibitor Silvestrol Blocks the Growth of Human Glioblastoma Cells by Inhibiting AKT/mTOR and ERK1/2 Signaling Pathway.

Authors:  Wei Zhang; Pian Gong; Qi Tian; Shoumeng Han; Jianfeng Wang; Peibang He; Yujia Guo; Guijun Wang; Qianxue Chen; Jie Huang; Mingchang Li
Journal:  J Oncol       Date:  2022-05-30       Impact factor: 4.501

3.  Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome.

Authors:  J J David Ho; Tyler A Cunningham; Paola Manara; Caroline A Coughlin; Artavazd Arumov; Evan R Roberts; Ashanti Osteen; Preet Kumar; Daniel Bilbao; Jonathan R Krieger; Stephen Lee; Jonathan H Schatz
Journal:  Cell Rep       Date:  2021-10-12       Impact factor: 9.423

4.  Design, Synthesis, and Cytotoxic Activity of Novel Natural Arylsulfonamide-Inspired Molecules.

Authors:  Wenbo Huang; Liqiao Shi; Manli Liu; Zhigang Zhang; Fang Liu; Tong Long; Shaohua Wen; Daye Huang; Kaimei Wang; Ronghua Zhou; Wei Fang; Hongtao Hu; Shaoyong Ke
Journal:  Molecules       Date:  2022-02-22       Impact factor: 4.411

5.  Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition.

Authors:  Biswendu Biswas; Ramdane Guemiri; Mandy Cadix; Céline M Labbé; Alina Chakraborty; Martin Dutertre; Caroline Robert; Stéphan Vagner
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

Review 6.  Targeting RNA structures with small molecules.

Authors:  Jessica L Childs-Disney; Xueyi Yang; Quentin M R Gibaut; Yuquan Tong; Robert T Batey; Matthew D Disney
Journal:  Nat Rev Drug Discov       Date:  2022-08-08       Impact factor: 112.288

Review 7.  Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection.

Authors:  Seyed Abdulmajid Ayatollahi; Javad Sharifi-Rad; Patrick Valere Tsouh Fokou; Gail B Mahady; Hafiz Ansar Rasul Suleria; Shivani Krishna Kapuganti; Kundlik Gadhave; Rajanish Giri; Neha Garg; Rohit Sharma; Daniel Ribeiro; Célia F Rodrigues; Željko Reiner; Yasaman Taheri; Natália Cruz-Martins
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

Review 8.  Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.

Authors:  Gaspar Taroncher-Oldenburg; Christin Müller; Wiebke Obermann; John Ziebuhr; Roland K Hartmann; Arnold Grünweller
Journal:  Microorganisms       Date:  2021-03-05

Review 9.  Antiviral plant-derived natural products to combat RNA viruses: Targets throughout the viral life cycle.

Authors:  Lucy Owen; Katie Laird; Maitreyi Shivkumar
Journal:  Lett Appl Microbiol       Date:  2022-01-25       Impact factor: 2.813

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.